Friederike Bachmann's research while affiliated with Charité Universitätsmedizin Berlin and other places

... Except for the deterioration in eGFR before pregnancy, we did not find any other predictors for adverse pregnancy outcomes. The strength of this study is the comparison with a matched control cohort with detailed information regarding baseline characteristics, allograft function parameters with the emphasis on dynamic changes, and a detailed long-term mean follow-up time in both cohorts including regular determinations of HLA antibodies [60]. Since common clinical indicators were not helpful for risk prediction, the use of current biomarkers such as sFlt-1 and PlGF and the detection and validation of new biomarkers derived from multiple organ and cellular sources need to be explored in future studies [61]. ...

... También se ha encontrado que los niveles de protección humoral disminuyen rápidamente también en los trasplantados renales que inicialmente respondieron a la vacunación, independientemente del tipo de inmunoglobulina y del ensayo utilizado. La pérdida de anticuerpos a los dos y cuatro meses después de la vacunación ocurre en un número sustancial de individuos que responden inicialmente, lo que puede resultar en una pérdida de protección contra COVID-19 [49]. ...

... The velocity of shear waves (SW) in tissue increases with increasing tissue stiffness (9). Previous studies have reported wide use of SWE to assess liver stiffness (10,11). After allo-HSCT, elastography has been demonstrated to improve the accuracy of early diagnosis of hepatobiliary complications (12). ...

... We demonstrated that antibody acquisition rates and antibody levels were low after two SARS-CoV-2 vaccinations in Japanese KT patients, consistent with previous reports from other countries and Japanese institutes [10,[15][16][17][18][19]. In our study, factors associated with antibody acquisition after the second vaccination were time since KT, ABO-I KT, and MMF use. ...

... Our data are in line with prior studies. Meanwhile, the therapy with mAbs in early-stage SARS-CoV-2 infections in high-risk groups is widely accepted, and clinical trials with mAbs have reported overall lower hospitalization rates in patients with mild-to-moderate COVID-19 [41][42][43]. However, previous studies have demonstrated that not all approved mAbs are suitable for treating the different variants of SARS-CoV-2 such as Omicron [44,45]. ...

... Eine Studie an 29 nierentransplantierten Patienten mit schlechten SARS-CoV-2-Antikörpertitern nach einer 1. Impfung zeigte, dass die Immunantwort auf eine 4. Dosis der COVID-19-Impfung durch eine Unterbrechung der Antimetabolitentherapie (z. B. MMF, Azathioprin) verbessert werden konnte[77].Bevor jedoch Empfehlungen zu diesem Ansatz abgegeben werden können, sind größere kontrollierte Studien erforderlich.Kalzineurininhibitoren (z. B. Cyclosporin A, Tacrolimus) haben in vitro antivirale Eigenschaften gegen mehrere Coronaviren gezeigt, darunter SARS-CoV und "middle east respiratory syndrome coronavirus" (MERS-CoV;[78,79]). ...

... REVIEW 3 authors concluded that further studies are needed to verify whether this difference remains after a third dose of vaccination. A study by Liefeldt [11] examined the predictors of the serological response to SARS-CoV-2 vaccination in kidney transplant patients. The study found that predictors of a weak response were the age at vaccination, time after kidney transplantation, immunosuppression, estimated glomerular filtration rate (eGFR) at vaccination and lymphocyte count at vaccination (Table 1a). ...

... However, the present results show that serologic testing of the vaccination response in immunocompromised KTR makes sense defining cohorts with either successful seroconversion as well as non-responding patients with better or worse chances for a successful booster vaccination. In this sub-cohort of non-responding KTR with better chances for successful booster vaccination, no potentially risky reductions in immunosuppressive therapy, as already proposed by others (25), may be necessary to achieve high seroconversion rates as shown here. Hereby it also can be considered that successful seroconversion is accompanied by, albeit relative (depending on the variants of the virus), protection from severe or fatal infections. ...

... Moreover, there is no consensus regarding the management of renal transplant recipients without allograft dysfunction with circulating de novo DSAs [16]. The impact of de novo anti-HLA DSAs on the development of ABMR is under investigation, as not all DSA-positive patients develop ABMR [17,18]. ...

... Although WNV was not detected in the Netherlands in the summer of 2021, in mid-September of 2022 a grey heron (Ardea cinerea) tested positive for the presence of WNV RNA in the province of North Holland, the Netherlands [9]. In other European countries, such as Germany and Hungary, WNV has been detected during summers of consecutive years, suggesting local persistence of the virus [10,11]. The first recorded finding of USUV in Europe occurred in 2001, in-and nearby Vienna, Austria [12]. ...